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Abstract:  Balanced  chromosomal  translocations  that  generate  chimeric  oncoproteins  are 
considered to be initiating lesions in the pathogenesis of acute myeloid leukemia. The most frequent 
is the t(15;17)(q22;q21), which fuses the 
leukemia  (APL).  An  increasing  proportion  of  APL  cases  are  therapy
develop  following  exposure  to  radiotherapy  and/or  chemotherapeutic  agents  that  target  DNA 
topoisomerase  II  (topoII),  particu
molecular  mechanisms  underlying  the  formation  of  the  t(15;17)  we  mapped  the  translocation 
breakpoints in a series of t-APLs, which revealed significant clustering according 
the  drug  exposure.  Remarkably,  in  approximately  half  of  t
mitoxantrone treatment for breast 
within an 8-bp “hotspot” region in 
topoII-mediated  DNA  cleavage  induced  by  mitoxantrone.
outside the “hotspot”, and the corresponding 
topoII  cleavage  sites.  The  observation  that  particular  r
susceptible to topoII-mediated DNA damage induced by epirubicin and mitoxantrone may underlie 
the propensity of these agents to cause APL.
Introduction. Acute  myeloid  leukemia  (AML)  is 
characterized by a spectrum of recurring chromosomal 
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osomal  translocations  that  generate  chimeric  oncoproteins  are 
considered to be initiating lesions in the pathogenesis of acute myeloid leukemia. The most frequent 
is the t(15;17)(q22;q21), which fuses the PML and RARA genes, giving rise to acute promyelocytic 
leukemia  (APL).  An  increasing  proportion  of  APL  cases  are  therapy-related  (t
develop  following  exposure  to  radiotherapy  and/or  chemotherapeutic  agents  that  target  DNA 
topoisomerase  II  (topoII),  particularly  mitoxantrone  and  epirubicin.  To  gain  insights  into 
molecular  mechanisms  underlying  the  formation  of  the  t(15;17)  we  mapped  the  translocation 
APLs, which revealed significant clustering according 
exposure.  Remarkably,  in  approximately  half  of  t-APL  cases  arising  following 
mitoxantrone treatment for breast cancer or multiple sclerosis, the chromosome 15 breakpoint fell 
bp “hotspot” region in PML intron 6, which was confirmed to be a pref
mediated  DNA  cleavage  induced  by  mitoxantrone. Chromosome  15  breakpoints  falling 
outside the “hotspot”, and the corresponding RARA breakpoints were also shown to be functional 
The  observation  that  particular  regions  of  the  PML 
mediated DNA damage induced by epirubicin and mitoxantrone may underlie 
the propensity of these agents to cause APL.
cute  myeloid  leukemia  (AML)  is 
characterized by a spectrum of recurring chromosomal 
abnormalities,  which  distinguish  biologically  and 
prognostically distinct subtypes of disease (reviewed 
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osomal  translocations  that  generate  chimeric  oncoproteins  are 
considered to be initiating lesions in the pathogenesis of acute myeloid leukemia. The most frequent 
genes, giving rise to acute promyelocytic 
related  (t-APL),  which 
develop  following  exposure  to  radiotherapy  and/or  chemotherapeutic  agents  that  target  DNA 
larly  mitoxantrone  and  epirubicin.  To  gain  insights  into 
molecular  mechanisms  underlying  the  formation  of  the  t(15;17)  we  mapped  the  translocation 
APLs, which revealed significant clustering according to the nature of 
APL  cases  arising  following 
or multiple sclerosis, the chromosome 15 breakpoint fell 
intron 6, which was confirmed to be a preferential site of 
Chromosome  15  breakpoints  falling 
breakpoints were also shown to be functional 
PML  and  RARA loci  are 
mediated DNA damage induced by epirubicin and mitoxantrone may underlie 
abnormalities,  which  distinguish  biologically  and 
prognostically distinct subtypes of disease (reviewed 
1). Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
To date, more than one hundred balanced chromosomal 
rearrangements  (translocations,  insertions  and 
inversions)  have  been  identified  and  cloned,
2 with 
evidence  suggesting  that  these  are  critical  initiating 
events in the pathogenesis of AML. Identification of 
the genes involved in chromosomal rearrangements has 
provided major insights into the regulation of normal 
hematopoiesis and how disruption of key transcription 
factors  and  epigenetic  modulators  promote  leukemic 
transformation. A number of genes, including MLL at 
11q23, NUP98 at 11p15, RARA at 17q21 and RUNX1 
at  21q22,  are  recurrent  targets  of  chromosomal 
rearrangements  in  AML,  being  fused  to  a  range  of 
potential  partner  genes  (reviewed 
3).  Interestingly, 
chromosomal  rearrangements  involving  these 
particular  loci  also  have  been noted  as  a  feature  of 
secondary acute leukemias arising as a complication of 
prior therapy involving drugs targeting topoisomerase 
II (topoII), which are widely used in the treatment of a 
variety of tumors.
4-13 TopoII is a critical enzyme that 
relaxes  supercoiled  DNA  and  removes  knots  and 
tangles from the  genome by transiently cleaving and 
religating  both  strands  of  the  double  helix  via  the 
formation  of  a  covalent  cleavage  intermediate
(reviewed 
14).  Epipodophyllotoxins  (e.g.  etoposide), 
anthracyclines (e.g.  epirubicin)  and  anthracenediones 
(e.g.  mitoxantrone)  act  as  topoII  poisons,  inducing 
DNA  damage  by  disrupting  the  cleavage-religation 
equilibrium and increasing the concentration of DNA 
topoII covalent complexes, which leads to apoptosis of 
the tumor cells.
14
The  association  between  exposure  to 
chemotherapeutic  agents  targeting  topoII  and 
development of leukemias with balanced chromosomal 
rearrangements has naturally implicated the enzyme in 
this  process,  but  the  mechanisms  involved  have 
remained subject to debate. One hypothesis takes into 
account reports that leukemia-associated translocations 
can  be  detected  in  hematopoietic  cells  derived  from 
healthy  individuals  without  overt  leukemia,
15,16
suggesting that administration of chemotherapy and/or 
radiotherapy  provides  a  selective  advantage  to 
progenitors  with  pre-existing  translocations  during 
regrowth of depopulated bone marrow. Moreover, the 
exposure to DNA damaging agents could lead to the 
acquisition of additional mutations that cooperate with 
the  chimeric  fusion  protein  generated  by  the 
translocation  to  induce  leukemic  transformation.  A 
second hypothesis, based on findings with transformed 
cells, raised the possibility that agents targeting topoII 
could  lead  to  the  formation  of  chromosomal 
translocations through an indirect mechanism involving 
induction of apoptotic nucleases.
17-20 Interestingly, Rolf 
Marschalek and colleagues provide evidence for a third 
potential  mechanism,  showing  that  the  region  of  the 
MLL locus  where  breakpoints  associated  with  infant 
and therapy-related leukemias cluster, colocalize with 
an  internal  promoter  element,  highlighting  the 
relevance of chromatin structure and DNA topology in 
the  genesis  of  chromosomal  translocations.
21 Finally, 
the  fourth  hypothesis,  which  is based on  increasing 
biochemical and genetic evidence, suggests that in the 
presence of a topo II-targeting chemotherapeutic agent, 
topoII plays a direct role in generating double-stranded 
DNA  breaks  in  regions  of  the  genome  that  are 
particularly  susceptible  due to  the  nature  of  the 
surrounding  chromatin.  Following  aberrant  repair, 
these  breaks  go  on  to  generate  leukemia-associated 
chromosomal translocations (reviewed 
22). 
Intriguingly, the nature of the drug exposure has a 
bearing  on  the  molecular  phenotype  of  the  resultant 
secondary leukemia, with translocations involving the 
MLL gene at 11q23 being particularly associated with 
etoposide  exposure.
10,23,24 Development  of  therapy-
related  acute  promyelocytic  leukemia  (t-APL), 
characterized by the t(15;17)(q22;q21), has been linked 
to treatment  with  mitoxantrone  and  epirubicin.
12,25,26
The t(15;17) leads to fusion of the gene encoding the 
myeloid  transcription  factor  RAR (Retinoic  Acid 
Receptor  Alpha)  at  17q21  with  a  gene  that  was 
previously  unknown  - designated  PML (for 
ProMyelocytic  Leukemia),  which  has  subsequently 
been found to be involved in growth suppression and 
regulation of apoptosis (reviewed 
27). This subtype of 
leukemia  is  of  particular  interest,  being  the  first  in 
which  molecularly  targeted  therapies  (i.e.,  all-
transretinoic acid [ATRA] and arsenic trioxide [ATO]) 
have  been  successfully  used  in  clinical  practice.
27
These agents act by inducing degradation of the PML-
RAR oncoprotein, leading to clinical remission and 
have  resulted  in  dramatic  improvements  in  clinical 
outcome  (reviewed 
28).  They  also  offer  a  potentially 
curative  approach  in  patients  with  t-APL  who  have 
already received significant doses of chemotherapy for 
their  previous  condition  and  may  be  close  to  the 
anthracycline ceiling, or who are considered unfit for 
conventional therapy.
29
The majority of t-APL cases arise in patients who 
have  undergone  treatment  for  breast  cancer,  where 
mitoxantrone  and  epirubicin  have  been  widely 
used.
12,25,26,30 In  this  setting,  cumulative  doses  of 
epirubicin of ≤720mg/m
2 have been associated with a 
secondary leukemia risk of 0.37% at 8 years.
31 As more 
patients  survive  their  primary  cancers,  secondary 
leukemias  are  becoming  an  increasing  healthcare 
problem.
32 Although  t-APL  remains  relatively 
uncommon,  two  case series  have  suggested  that  the 
incidence has risen in recent years, with up to 20% of 
APL patients presenting with secondary disease.
25,30Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
Figure  1. Distribution  of  translocation  breakpoints  within  the  PML  and  RARA loci  in  t-APL  cases  arising  following  epirubicin  and 
mitoxantrone. PML exons are represented by red boxes, RARA exons in blue and introns are represented by black lines. Arrows indicate the 
location of PML and RARA translocation breakpoints identified by long-range PCR and sequence analysis in patients with t-APL arising 
following mitoxantrone (red arrows) or epirubicin (green arrows). In 12 patients mitoxantrone was used for treatment of multiple sclerosis 
(MS). In the remaining 5 patients with mitoxantrone-related APL and the 6 patients with t-APL following epirubicin, these agents were used 
for prior breast cancer. Significant breakpoint clustering was observed, with a “hotspot” identified in PML intron 6 (position 1482-9) in 
mitoxantrone-related APL (following use of the drug for MS or breast cancer) and separate clusters associated with APL arising following 
epirubicin  exposure.  Chromosomal  breakpoints  were  confirmed  to  be  preferential  sites  of  drug-induced  topoisomerase  II  cleavage  in 
functional assays (see Figure 2). Adapted from Mays et al.
42 with permission.
Investigation  of  Molecular  Mechanisms  in 
Mitoxantrone-Related t-APL. As a first step to gain 
insights into mechanisms underlying formation of the 
t(15;17) we used long-range polymerase chain reaction 
(PCR) and sequence analysis  to  define chromosomal 
breakpoint  locations,  comparing  the  pattern  between 
patients presenting de novo (n=35) and those with t-
APL  occurring  following  exposure  to  mitoxantrone 
(n=6)  or  other  agents/radiation  therapy  (n=7).
33
Analysis of diagnostic samples from large cohorts of 
patients  with  de  novo APL  has  established  that  the 
majority of chromosome 15 breakpoints fall within 3 
breakpoint cluster regions (bcr) i.e. in intron 3 (bcr3), 
intron 6 (bcr1) and exon 6 (bcr2) of the PML locus, 
accounting  for  approximately  40%,  55%  and  5%  of 
cases respectively.
34 Chromosome 17 breakpoints fall 
within the ~17kb intron 2 of the RARA locus, such that 
the PML-RAR fusion retains key functional domains 
mediating  DNA  binding  and  interaction  with 
coactivator/corepressors,  retinoid-X-receptor  and 
ligand (i.e. retinoic acid).
27 While breakpoints observed 
in  de  novo APL  appeared  broadly  distributed, 
chromosome  15  breakpoints  of  each  of  the 
mitoxantrone-related t-APLs fell within PML intron 6, 
with 4 cases clustering within an 8-bp region (position 
1482-9)(see Figure 1).
33 Given that this intron is over 
1kb in length, this clustering of breakpoints was highly 
unlikely to have occurred by chance (p<0.001 by scan 
statistics).  To  investigate  this  further,  we  used  a 
functional in vitro assay, in which substrates containing 
the  normal  homologues  of  the  PML and  RARA
translocation  breakpoints  are  5’-end-labelled  and 
exposed  to  clinically  relevant  topoII  poisons  (e.g. 
mitoxantrone, epirubicin, etoposide) in the absence or 
presence of human topoII alpha; cleavage complexes 
are trapped and cleavage sites mapped in relation to the 
observed  translocation  breakpoints  at  the  sequence 
level.
35-37 These  experiments  demonstrated  that  the 
breakpoint  “hotspot,”  identified  in  t-APL  patients 
previously treated with mitoxantrone for breast cancer, 
corresponded precisely to a preferential mitoxantrone-
induced  topoII-dependent  DNA  cleavage  site  at 
position  1484  (see  Figure  2).
33 Moreover,  each 
observed  translocation  breakpoint  within  the  RARA
locus  on  chromosome  17  was  confirmed  to  be  a 
preferred site of topoII-mediated DNA damage induced 
by mitoxantrone (Figure 2).
33
These data strongly implicated mitoxantrone in the
etiology of t-APL. However, it is important to consider
that  the  study  of  patients  developing  leukemiaMediterr J Hematol Infect Dis 2011; 3: Open Journal System
Figure 2. Demonstration of mitoxantrone-induced topoisomerase II dependent DNA cleavage at translocation breakpoints in therapy-related 
APL. A) In vitro DNA topoisomerase II (topoII) cleavage assay carried out for a PML substrate containing the breakpoints of 4 treatment-
related APL (t-APL) cases (F-8,-24,-25,-27) within the 8-bp breakpoint “hotspot” (positions 1482-1489). Patients received combination 
chemotherapy including the topoII poison mitoxantrone for breast cancer. Control reactions were carried out in the absence of topoII (lanes 
1-4),  and  in  the  presence  of  etoposide  (VP16),  etoposide  catechol  (VP16-OH),  etoposide  quinone  (VP16-Q)  and  mitoxantrone  (Mit).
Dideoxy sequencing reactions of the substrate are shown in lanes 5-8. Cleavage reactions were carried out by exposure to human topoII in 
the absence of drug (lane 9), and in the presence of etoposide (lane 10), etoposide catechol (lane 11), etoposide quinone (lane 12) and 
mitoxantrone (lane 13). Additional cleavage reactions were carried out to evaluate the heat-stability of cleavage complexes formed by 
incubation at 75C for 10 min (lanes 14-18). The nucleotide shown by the dash is the 5’side of the cleavage site (-1 position), which 
corresponds to the der(15) and der(17) translocation breakpoints in 4 cases of mitoxantrone-related APL (far right). The cleavage site at 
position 1484 was observed in the absence of drug, and in the presence of etoposide, both etoposide metabolites and mitoxantrone (lanes 9-
13). Cleavage at this position was the strongest site observed in the presence of mitoxantrone (lane 13). Furthermore, the complexes formed 
at this site were shown to be heat-stable in the presence of mitoxantrone (lane 18). Interestingly, a cleavage site at position 1502 is also 
observed, which corresponds to a breakpoint detected in a case of de novo APL.
B) TopoII cleavage assay of normal homologue of der(15) and der(17) RARA translocation breakpoints in APL of one of the mitoxantrone-
related cases (F-8). The substrate spanning positions 2603 to 2871 of RARA intron 2 contained the translocation breakpoints. Dash at right 
shows (-1) position of cleavage site corresponding to der(15) and der(17) translocation breakpoints (arrow far right). Adapted from Mistry et 
al.
33 with permission.
following  cancer  therapy presents  a  challenge,  given 
that they have often been exposed to multiple cytotoxic
drugs  in  addition  to  radiotherapy.  This  makes  it 
difficult  to  identify  the  causative  agent  with  any 
certainty.  Moreover,  such  patient  populations  could 
feasibly be enriched for individuals at particular risk of 
leukemia,  having  already  developed  one  form  of 
cancer.  Therefore,  to  provide  further  insights  into 
molecular mechanisms in topoII-related leukemias, we 
analyzed a cohort of 12 patients collected from across 
Europe who developed APL following the use of single 
agent  mitoxantrone  to  treat  a  benign  condition, 
multiple  sclerosis  (MS),  and  in  whom  there  was  no 
history  of  previous  cancer.
38 Chromosome  15 
breakpoints  again  were  found  to  cluster  at  position 
1484  within  PML intron  6.  Furthermore,  shared 
chromosome 17 breakpoints that were preferential sites 
of mitoxantrone-induced topoII cleavage in functional 
assays were identified within RARAintron 2 (Figure 
1).
38 The  series  of  mitoxantrone-related  t-APL  cases 
analyzed has been further extended recently, with the 
chromosome  15  breakpoint  found  to  fall  within  the 
“hotspot” region in 12 of 23 cases (52%).
33,38,39
Comparison  of  the  genomic  breakpoint  junction 
regions  with  the  native  genes  showed  that 
translocations  in  mitoxantrone-related  t-APL  were 
reciprocal,  generally  without  loss  or  gain  of 
nucleotides.
33,38 Presence  of  sequence  homologies 
between PML and RARA suggests that topoII-mediated 
DNA  damage  may  be  repaired  by  the  canonical 
nonhomologous end-joining (NHEJ) or the alternative 
end-joining  (alt-NHEJ)  pathway,  which  require 
minimal  overlapping  sequences  between 
nonhomologous  chromosomes  to  repair  double-
stranded  DNA  breaks  (reviewed
40).  Using  the 
information derived from genomic breakpoint junction 
sequence  analysis  and  in  vitro cleavage  assays,  the 
knowledge  that  topoII introduces  staggered  nicks  inMediterr J Hematol Infect Dis 2011; 3: Open Journal System
Figure 3. Model for formation of the t(15;17) in a case of mitoxantrone-related t-APL (case F8) following topoII induced cleavage in PML
and RARA loci with 4-base 5’ overhangs and aberrant DNA repair. Native PML and RARA sequences are red and blue, respectively. The 
processing includes exonucleolytic nibbling to form two-base (der(15)) or single-base (der(17)) homologies and creation of both breakpoint 
junctions by error-prone nonhomologous end-joining (NHEJ). In formation of the der(15), positions 1487-1488 on the antisense strand of 
PML are lost by exonucleolytic nibbling (pink) before NHEJ joins the indicated bases. Positions 1485-1487 on the sense strand of PML are 
lost by exonucleolytic nibbling (pink) and the der(17) forms by NHEJ. Template-directed polymerization of the relevant single-stranded 
overhangs fills in any gaps (light blue). Each RARA overhang is preserved completely. Adapted from Mistry et al.
33 with permission.
DNA  with  4-bp  overhangs
22 and  considering  known 
mechanisms of DNA repair it was possible to construct 
models by which the t(15;17) may have been formed in 
each  case  analyzed  (see  Figures  3  &  4).  Taken 
together, these data provide very strong evidence that 
mitoxantrone is a causative agent in the pathogenesis 
of t-APL.
Investigation  of  Molecular  Mechanisms  in  t-APL
Cases  Arising  Following  Other  TopoII Poisons. 
Epirubicin  exposure  has  been  linked  to  secondary 
leukemias  with  a  range  of  balanced  rearrangements, 
including translocations involving the MLL locus, core 
binding  factor  leukemias  and  t-APL  with  the 
t(15;17).
31,41 In  order  to  gain  further  insights  into 
molecular  mechanisms  underlying  epirubicin-related 
leukemias,  we  characterized  t(15;17)  genomic 
breakpoint junction regions in a series of 6 t-APL cases 
that arose following breast cancer therapy.
42 Epirubicin 
was  generally  used  as  a  component  of  combination 
chemotherapy, with a median latency period from first 
exposure to presentation of t-APL of 26 months (range 
18-48  months).  Although  the  number  of  cases 
examined was small, significant breakpoint clustering 
was observed in both the PML and RARA loci (P= .009 
and  P  =  .017,  respectively),  with  PML breakpoints 
lying  outside  the  mitoxantrone-associated  “hotspot” 
region (Figure 1). Functional assays demonstrated that 
recurrent breakpoints identified in the PML and RARA
loci in epirubicin-related t-APL were preferential sites 
of topoII-induced DNA damage that were enhanced by 
epirubicin.
42 Again,  using  the  same  approach  as  for 
mitoxantrone-related  t-APLs,  models  could  be 
constructed to explain the formation of the t(15;17) in 
APLs arising following epirubicin exposure.
42
There  also  have  been  reports  of  t-APL  occurring 
following  treatment  with  other topoII  poisons  (e.g., 
etoposide)  used  for  lymphomas  and  various  solid 
tumors, as well as Langerhans cell histiocytosis.
12,25,43
To  determine  whether  topoII–mediated  cleavage  is 
relevant to other drugs associated with t-APL, we also 
have studied a patient in whom APL developed after 
treatment  for  laryngeal  carcinoma  that  included 
etoposide  and  doxorubicin.
33 Etoposide  and  its
metabolites and doxorubicin induced topoII to cleave
DNA at the PML and RARA translocation breakpoints. 
Moreover, the cleavage sites could recombine to form
the der(15) and der(17) breakpoint junctions observed 
in  this  patient.  Taken  together,  these  results  suggest 
that topoII–mediated cleavage is a general mechanism
causing  DNA  damage  in  APL  that  develops  after 
treatment with various agents that target topoII (FigureMediterr J Hematol Infect Dis 2011; 3: Open Journal System
Figure 4. Model summarizing formation of reciprocal translocation breakpoint junctions in treatment related APL directly by generation of 
drug-stimulated topoisomerase II cleavage complexes and near-precise or precise NHEJ repair. Adapted from Felix et al.
22 with permission.
4).
Concluding  Remarks.  While  therapy-related 
leukemias  are  still  relatively  uncommon,  they  are 
characterized  by  the  same  range  of  cytogenetic 
abnormalities that are found in cases of AML arising 
de novo.
44,45 Indeed, greater understanding of therapy-
related leukemias may provide significant insights into 
the biology of their de novo counterparts. For example, 
defining the latency period between first exposure to a 
leukemogenic  agent  (e.g.  mitoxantrone)  and 
presentation with full blown leukemia, provides clues 
to the timeframe between acquisition of chromosomal 
rearrangements such as the t(15;17) and progression to 
leukemia  in  the  de  novo setting.  Analysis  of  t-APL 
cases suggests that the median time to develop APL 
from the formation of the t(15;17) is ~27 months,
33,38,42
implying  the  need  for  cooperating  mutations.  While 
logistically  challenging,  therapy-related  leukemias 
afford  the  opportunity  for  tracking  the  stepwise 
acquisition  of  mutations  that  are  required  for 
progression to full-blown leukemia,
46,47 and which may 
be  of  relevance  to  the  pathogenesis  of  leukemias 
arising de novo. While we have observed a few cases 
of  t-APL  that  present  within  12  months  from  first 
mitoxantrone exposure, latency periods in the majority 
of cases are much longer. This may account for why, 
even  if  the  t(15;17)  were acquired  in  some  cases  in 
utero, de novo pediatric APL only very rarely presents 
in infancy.  
A number of studies conducted over the last three 
decades  have  served  to  identify  specific  dosing 
schedules or particular agents that are associated with 
high rates of induction of secondary leukemias,
32,48-51
leading  to  the  development  of  effective  alternative 
treatment  protocols  that  are  substantially  safer.
52-54
However,  the  study  of  patients  with  t-APL  has 
demonstrated that  therapy-related leukemias  also  can 
occur in patients subject to very low level exposure, as 
exemplified  by  a  case  of  APL  involving  the  PML
breakpoint “hotspot” arising following a single 15 mg 
dose of mitoxantrone used as adjuvant chemotherapy 
for breast cancer.
33 Epidemiology studies conducted in 
MS patients treated with mitoxantrone have suggested 
that the risk of development of secondary leukemia is 
~1 in 370,
55,56 with the majority of reported cases being 
t-APL.  This  raises  key questions  as  to  the  extent  to 
which  the  play  of  chance  is  involved  in  the Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
development of therapy-related leukemias, as well as 
the relative importance of patient predisposition to the 
development  of  this  complication.  A  number  of 
prerequisites have to be satisfied to develop leukemia 
following  treatment  with  a  topoII  poison.  Firstly, 
double-strand  DNA  breaks  must  occur  within  two 
genes  with  the  potential  to  form  oncogenic  fusions. 
These breaks then need to be repaired to generate in-
frame  functional  chimeric  fusion  genes.  This 
translocation  event  needs  to  occur  in  a  progenitor 
permissive for leukemic transformation and finally the 
necessary  cooperating  mutations  are  acquired.  While 
our studies have provided evidence that topoII plays a 
direct  role  in  mediating  DNA  damage  that  leads  to 
formation  of  the  t(15;17)  in  t-APL,  a  key  question 
remains as to whether the enzyme is also involved in 
the  formation  of  chromosomal  translocations  in  de 
novo leukemias. Exposure to environmental toxins and 
agents  targeting  topoII  has  been  implicated  in  the 
development  of  infant  leukemia  with  translocations 
involving MLL at  11q23.
57-59 Interestingly,  recent 
evidence lends further support for topoII in the etiology 
of chromosomal translocations, inducing DNA damage 
in the TMPRSS2 and ERG loci in response to androgen 
signalling,  leading  to  formation  of  fusion  genes 
involved in prostate cancer.
60
It is readily conceivable that genetic susceptibility 
to  primary  tumors  due  to  mutations  or  functional 
variants  for  example  in  DNA  repair  pathways  also 
could  increase  the  risk of development of  secondary 
leukemias.  Interestingly,  a  recent  genome-wide 
association  study  has  implicated  variants  in  the 
PRDM1 gene at  6q21 in  the  development  of second 
neoplasms  in  children  treated  with  radiotherapy  for 
Hodgkin’s  disease,
61 whereas  whole  genome 
sequencing applied in a case of therapy-related AML 
arising  from  early-onset  BRCA1/2  mutation-negative 
breast and ovarian cancer revealed a novel TP53 cancer 
susceptibility  mutation.
62 The  spectrum  of  resultant 
leukemias  could  reflect  the  nature  of  the  genetic 
susceptibility as well as the agents preferentially used 
for  the  particular  primary  condition,  as  would  be 
suggested  by  the  propensity  of  etoposide  to  induce 
secondary leukemias involving the MLL gene at 11q23 
and  epirubicin  and  mitoxantrone  to  induce  t-APL. 
Moreover, genetic variation in the handling of a range 
of specific cytotoxic agents could affect an individual’s 
risk of developing secondary leukemia (reviewed 
63). 
Indeed,  it  has  recently  been  reported  that  genetic 
variants of genes encoding drug-metabolizing enzymes 
and  components  of  DNA  repair  pathways  are 
associated with increased susceptibility to development 
of t-APL in patients with MS receiving mitoxantrone.
64
Dissecting  out  the  relative  importance  of  these 
factors represents a considerable challenge. It requires 
the  analysis  of substantial  patient  cohorts, which are 
well  characterized  both  in  terms  of  their  primary 
tumors,  prior  cytotoxic  therapy  and  cytogenetic  and 
molecular  profile  of  the  secondary  leukemias. 
Nevertheless, significant progress in this research area 
is  likely to  be  fruitful  allowing  not  only  the 
development  of  more  individualized  and  safer 
approaches  to  treatment  of  primary  tumors,  but  also 
(potentially)  providing  insights  into  molecular 
mechanisms  underlying  the  pathogenesis  of  de  novo
leukemias.  Thus,  it  could  afford  improved 
understanding of AML as a whole. 
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